Head-to-head evidence
BAY3283142 vs Praliciguat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Soluble guanylate cyclase · full Chronic Kidney Disease pipeline
BAY3283142
Developed by Bayer
NCT06522997 · Phase 2 · completed
The study used random assignment, quadruple masking, and a placebo control with a large enrollment of 1,222 participants. Its primary endpoint was the surrogate measure of change in UACR, and the primary comparison cannot yet be judged because results are not posted.
Next expected readout: October 2026 · NCT07722585 (registry estimate)
Praliciguat
Developed by Akebia Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07268638 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAY3283142's landscape · Praliciguat's landscape